-
Je něco špatně v tomto záznamu ?
Acute and Long-Term Scar Characterization of Venous Ethanol Ablation in the Left Ventricular Summit
SC. Fuentes Rojas, M. Malahfji, L. Tavares, A. Patel, PA. Schurmann, AS. Dave, C. Tapias, D. Rodríguez, LC. Sáenz, S. Korolev, G. Papiashvili, P. Peichl, J. Kautzner, K. Blaszyk, K. Malaczynska-Rajpold, T. Chen, P. Santangeli, DJ. Shah, M. Valderrábano
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
R01 HL115003
NHLBI NIH HHS - United States
- MeSH
- gadolinium MeSH
- jizva MeSH
- katetrizační ablace * metody MeSH
- komorová tachykardie * chirurgie MeSH
- kontrastní látky MeSH
- lidé MeSH
- mezikomorová přepážka * MeSH
- srdeční arytmie chirurgie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
BACKGROUND: Venous ethanol ablation (VEA) can be effective for ventricular arrhythmias from the left ventricular summit (LVS); however, there are concerns about excessive ablation by VEA. OBJECTIVES: The purpose of this study was to delineate and quantify the location, extent, and evolution of ablated tissue after VEA as an intramural ablation technique in the LVS. METHODS: VEA was performed in 59 patients with LVS ventricular arrhythmias. Targeted intramural veins were selected by electrograms from a 2F octapolar catheter or by guide-wire unipolar signals. Median ethanol delivered was 4 mL (IQR: 4-7 mL). Ablated areas were estimated intraprocedurally as increased echogenicity on intracardiac echocardiography (ICE) and incorporated into 3-dimensional maps. In 44 patients, late gadolinium enhancement cardiac magnetic resonance (CMR) imaged VEA scar and its evolution. RESULTS: ICE-demonstrated increased intramural echogenicity (median volume of 2 mL; IQR: 1.7-4.3) at the targeted region of the 3-dimensional maps. Post-ethanol CMR showed intramural scar of 2.5 mL (IQR: 2.1-3.5 mL). Early (within 48 hours after VEA) CMR showed microvascular obstruction (MVO) in 30 of 31 patients. Follow-up CMR after a median of 51 (IQR: 41-170) days showed evolution of MVO to scar. ICE echogenicity and CMR scar volumes correlated with each other and with ethanol volume. Ventricular function and interventricular septum remained intact. CONCLUSIONS: VEA leads to intramural ablation that can be tracked intraprocedurally by ICE and creates regions of MVO that are chronically replaced by myocardial scar. VEA scar volume does not compromise septal integrity or ventricular function.
Federal Research and Clinical Center of the FMBA of Russia Moscow Russia
Fundación Cardioinfantil Bogotá Colombia
Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA
Houston Methodist DeBakey Heart and Vascular Center Houston Methodist Hospital Houston Texas USA
Institute for Clinical and Experimental Medicine Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010717
- 003
- CZ-PrNML
- 005
- 20230801132609.0
- 007
- ta
- 008
- 230718s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jacep.2022.08.035 $2 doi
- 035 __
- $a (PubMed)37166222
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Fuentes Rojas, Stephanie C $u Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA
- 245 10
- $a Acute and Long-Term Scar Characterization of Venous Ethanol Ablation in the Left Ventricular Summit / $c SC. Fuentes Rojas, M. Malahfji, L. Tavares, A. Patel, PA. Schurmann, AS. Dave, C. Tapias, D. Rodríguez, LC. Sáenz, S. Korolev, G. Papiashvili, P. Peichl, J. Kautzner, K. Blaszyk, K. Malaczynska-Rajpold, T. Chen, P. Santangeli, DJ. Shah, M. Valderrábano
- 520 9_
- $a BACKGROUND: Venous ethanol ablation (VEA) can be effective for ventricular arrhythmias from the left ventricular summit (LVS); however, there are concerns about excessive ablation by VEA. OBJECTIVES: The purpose of this study was to delineate and quantify the location, extent, and evolution of ablated tissue after VEA as an intramural ablation technique in the LVS. METHODS: VEA was performed in 59 patients with LVS ventricular arrhythmias. Targeted intramural veins were selected by electrograms from a 2F octapolar catheter or by guide-wire unipolar signals. Median ethanol delivered was 4 mL (IQR: 4-7 mL). Ablated areas were estimated intraprocedurally as increased echogenicity on intracardiac echocardiography (ICE) and incorporated into 3-dimensional maps. In 44 patients, late gadolinium enhancement cardiac magnetic resonance (CMR) imaged VEA scar and its evolution. RESULTS: ICE-demonstrated increased intramural echogenicity (median volume of 2 mL; IQR: 1.7-4.3) at the targeted region of the 3-dimensional maps. Post-ethanol CMR showed intramural scar of 2.5 mL (IQR: 2.1-3.5 mL). Early (within 48 hours after VEA) CMR showed microvascular obstruction (MVO) in 30 of 31 patients. Follow-up CMR after a median of 51 (IQR: 41-170) days showed evolution of MVO to scar. ICE echogenicity and CMR scar volumes correlated with each other and with ethanol volume. Ventricular function and interventricular septum remained intact. CONCLUSIONS: VEA leads to intramural ablation that can be tracked intraprocedurally by ICE and creates regions of MVO that are chronically replaced by myocardial scar. VEA scar volume does not compromise septal integrity or ventricular function.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a jizva $7 D002921
- 650 _2
- $a kontrastní látky $7 D003287
- 650 12
- $a komorová tachykardie $x chirurgie $7 D017180
- 650 12
- $a katetrizační ablace $x metody $7 D017115
- 650 _2
- $a gadolinium $7 D005682
- 650 _2
- $a srdeční arytmie $x chirurgie $7 D001145
- 650 12
- $a mezikomorová přepážka $7 D054088
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Malahfji, Maan $u Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA
- 700 1_
- $a Tavares, Liliana $u Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA
- 700 1_
- $a Patel, Apoor $u Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA
- 700 1_
- $a Schurmann, Paul A $u Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA
- 700 1_
- $a Dave, Amish S $u Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA
- 700 1_
- $a Tapias, Carlos $u Fundación Cardioinfantil, Bogotá, Colombia
- 700 1_
- $a Rodríguez, Diego $u Fundación Cardioinfantil, Bogotá, Colombia
- 700 1_
- $a Sáenz, Luis Carlos $u Fundación Cardioinfantil, Bogotá, Colombia
- 700 1_
- $a Korolev, Sergey $u Federal Research and Clinical Center of the FMBA of Russia, Moscow, Russia
- 700 1_
- $a Papiashvili, Giorgi $u Jo Ann Medical Center, Tbilisi, Georgia
- 700 1_
- $a Peichl, Petr $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Kautzner, Josef $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
- 700 1_
- $a Blaszyk, Krzysztof $u Poznan University of Medical Sciences, Poznan, Poland
- 700 1_
- $a Malaczynska-Rajpold, Katarzyna $u Arrhythmia Unit, Royal Brompton Hospital, Heart Division, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
- 700 1_
- $a Chen, Tiffany $u Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
- 700 1_
- $a Santangeli, Pasquale $u Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
- 700 1_
- $a Shah, Dipan J $u Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA
- 700 1_
- $a Valderrábano, Miguel $u Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA. Electronic address: mvalderrabano@houstonmethodist.org
- 773 0_
- $w MED00193518 $t JACC. Clinical electrophysiology $x 2405-5018 $g Roč. 9, č. 1 (2023), s. 28-39
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37166222 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132605 $b ABA008
- 999 __
- $a ok $b bmc $g 1963265 $s 1196982
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 9 $c 1 $d 28-39 $e 20221026 $i 2405-5018 $m JACC. Clinical electrophysiology $n JACC Clin Electrophysiol $x MED00193518
- GRA __
- $a R01 HL115003 $p NHLBI NIH HHS $2 United States
- LZP __
- $a Pubmed-20230718